Introduction: One-third of the patients with pancreatic cancer present with locally
degrees or arterial contact exceeding 90 degrees (Table 1) without distant metastases. 3 The initial treatment for LAPC is a systemic chemotherapy. 4 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) is the preferred treatment, based upon the results of a randomized study showing a significant and relevant improvement in overall survival (OS) compared with gemcitabine in patients with metastatic disease (median OS 11.1 vs 6.8 months; P < 0.0001). 5 No randomized trials have been published on FOLFIRINOX in patients with LAPC. However, several case series have shown favorable survival with a median OS ranging from 10.0 to 32.7 months. 6 Patients who do not develop the metastatic disease during FOLFIRINOX may benefit from subsequent radiotherapy (RT) for local control. 4 The objective of this study was to assess survival outcomes and toxicity of FOLFIRINOX followed by RT in patients with LAPC. | 1023
| METHODS
(n = 1), gastrointestinal bleeding (n = 1), and ascites (n = 1). All serious adverse events of the FOLFIRINOX treatment are summarized in Table 2 . No deaths were attributed to FOLFIRINOX. Only one (6%) patient had a serious adverse event of grade 3 of diarrhea during RT.
Three (14%) patients underwent an exploratory laparotomy after Our median OS and PFS is lower than found in the meta-analysis.
However, most studies in the meta-analysis were retrospective, which may cause selection bias. On the other hand, we used a staging laparoscopy before the treatment to rule out the occult metastatic disease. This approach is based upon two studies that have shown that 34% and 35% of patients with LAPC are found to have clinically and radiographically-undetermined metastatic disease during staging laparoscopy.
21,22
The FOLFIRINOX treatment toxicity of 59% serious adverse events is comparable to the other studies published about this treatment regimen, with the meta-analysis showing a 60% of serious adverse events during the treatment. Despite this high toxicity profile, FOLFIRINOX showed a better quality of life than gemcitabine in the PRODIGE 4 trial, probably by deferring definitive deterioration. 23 RT had a very low rate of serious adverse events (6%) in our study and therefore is safe to give as the subsequent treatment after the first-line FOLFIRNOX. However, whether conventional RT improves survival for LAPC patients has not been evaluated in a randomized controlled trial. 4 In regard of chemoradiotherapy, in 2016 Hammel et al 24 published the LAP07 randomized controlled trial which randomized patients with LAPC for induction chemotherapy (gemcitabine vs gemcitabine and erlotinib), followed by a second randomization of continuing chemotherapy vs chemoradiotherapy (54 Gy plus capecitabine). During the interim analysis, the study was stopped as it reached the early stopping boundaries for futility.
However, the study did not show a significant median OS benefit between continuing chemotherapy or subsequent chemoradiotherapy after induction chemotherapy with a median survival of 16.5 vs 15.2 months, respectively. The major disadvantage of conventional fractionated RT for pancreatic cancer is that although the pancreas is relatively radioresistant, the surrounding organs are highly radiosensitive. 25 In the last years, stereotactic body RT (SBRT) has emerged as the preferred RT after the systemic chemotherapy for LAPC. SBRT allows for a higher dose of RT to the pancreatic tumor with less radiation to the surrounding organs. 26 A low rate of serious adverse events (7%) was also seen by Mellon et al 27 when SBRT was given as therapy for borderline resectable and locally advanced pancreatic cancer after induction chemotherapy.
In our study, two patients (9%) underwent a resection with, both being a radical resection. This rate was lower than the pooled resection rate of 28% as shown in the meta-analysis. 6 In our clinic, the decision to do an exploration after induction therapy is based on the same definitions for LAPC. So arterial tumor encasement should not exceed 90 degrees and venous encasement should not exceed 270 degrees. These more conservative criteria for exploration could have led to a lower resection rate than given in other studies.
Furthermore, the meta-analysis did not detect an association between a studied resection rate and survival. Some studies report remarkable survival outcomes in LAPC patients after induction FOLFIRINOX and resection. However, these patients are highly selective and the favorable outcomes may be largely attributable to therapy was achieved. 4 In our clinic, the decision to do an exploration after induction therapy is based on the same definitions for LAPC. So arterial tumor encasement should not exceed 90 degrees and venous encasement should not exceed 270 degrees. These more conservative criteria for exploration could have led to a lower resection rate than given in other studies. Future studies should determine which patients could potentially benefit from a resection after induction chemotherapy.
Our study has several limitations. The main limitation is that the sample size of patients who received the full treatment is small to draw definitive conclusions. However, despite the small sample size, this study gives an overview of how many patients eventually receive induction chemotherapy after the diagnosis of LAPC. Furthermore, there is no general consensus in the definition for LAPC that can help generalize the interpretation of different treatment regimens.
Although the Dutch Pancreatic Cancer Group definitions for LAPC are more conservative than the most commonly used definitions such as NCCN and AHPBA/SSO/SSAT definitions, 30, 31 there is no evidence that there is a difference in survival because of these criteria. In addition, conventional RT was used in this study while SBRT can maybe induce a better local control as mentioned above.
In conclusion, this study gives an overview of the current practice and strategy of patients with LAPC in the Netherlands. FOLFIRINOX followed by RT can be offered to a limited number of patients, but it could be considered safe and shows promising survival results for patients with LAPC. Randomized controlled trials are needed to determine the value of RT, and resection in addition to FOLFIRINOX in patients with LAPC.
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